Mode
Text Size
Log in / Sign up

Xeno-ADM for fascia lata repair reduces compartment pressure and inflammatory markers in oral cancer reconstructionXeno-ADM Material Improves Recovery for Oral Cancer Reconstruction

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider Xeno-ADM for fascia lata repair to reduce compartment pressure and improve functional recovery in oral cancer reconstruction.

This randomized controlled trial enrolled 200 patients undergoing anterolateral thigh (ALT) flap reconstruction for oral cancer. The study compared the use of xenogeneic acellular dermal matrix (Xeno-ADM) for fascia lata repair against primary closure.

Primary outcomes showed that the Xeno-ADM group had significantly lower compartment pressure and lower inflammatory markers (CRP) in drainage fluid on POD 3 and 5. Additionally, serum muscle injury biomarkers (creatine kinase) were significantly lower in the Xeno-DM group on POD 1 and 5. Secondary outcomes showed no difference in drainage duration between the two groups.

Functional outcomes, including gait recovery, pain scores, and lower-limb function, were superior in the Xeno-ADM group. Specifically, patients in the Xeno-ADM group demonstrated faster gait recovery, lower pain scores at POD 7, and better lower-limb function at 1 and 6 months.

Safety data regarding adverse events or tolerability were not reported. The study was limited by a single-blind design and the absence of reported p-values or confidence intervals. Xeno-ADM is suggested as a potentially safer and more effective approach for fascia lata repair to improve functional recovery and reduce inflammatory burdens.

How this fits prior evidence

How this fits prior evidence: This study addresses a gap in surgical management for oral cancer reconstruction. While previous coverage focused on risk factors such as dietary inflammatory potential, metabolic syndrome (HR: 1.12), and PD-L1 expression, this finding provides specific evidence regarding the surgical management of the reconstruction phase for oral cancer patients.

Researchers conducted a trial to see how a specific material, called Xeno-ADM, affects patients undergoing a type of reconstruction surgery for oral cancer. The study included 200 patients who received an anterolateral thigh flap. The goal was to see if using this material to repair the fascia lata would improve recovery compared to standard primary closure.

The results showed that patients who received the Xeno-ADM material had lower compartment pressure and lower levels of inflammatory markers and muscle injury markers in their bodies. Additionally, these patients reported lower pain scores and showed better lower-limb function and faster walking recovery at one and six months after surgery.

While the study suggests that Xeno-ADM is a safe and effective way to reduce physical stress on the body during surgery, it is important to note that this was a single-blind trial. Because specific statistical values were not provided, these findings should be discussed with a surgical team to determine the best approach for individual patient care.

What this means for you:
Xeno-ADM may reduce inflammation and improve walking and pain scores for oral cancer reconstruction patients.

Common questions

What are the benefits of using Xeno-ADM for this surgery?

Patients who received the Xeno-ADM material showed lower compartment pressure and lower levels of inflammatory markers and muscle injury biomarkers. They also experienced faster gait recovery, lower pain scores at day 7, and better lower-limb function at both 1 and 6 months after the procedure.

How does this treatment affect recovery compared to standard methods?

The study found that patients using Xeno-ADM had superior functional outcomes compared to those who had a primary closure. While the duration of drainage did not differ between the two groups, the Xeno-ADM group showed improved mobility and lower pain levels.

Is this treatment safe for oral cancer patients?

The trial suggests that Xeno-ADM is a safe and effective approach for fascia lata repair. It may reduce the physical and inflammatory burdens on the body, though the study was a single-blind trial and specific safety data were not fully detailed.

Study Details

Study typeRct
Sample sizen = 200
EvidenceLevel 2
Follow-up6.0 mo
PublishedOct 2026
View Original Abstract ↓
BACKGROUND: Donor-site management after anterolateral thigh (ALT) flap harvest is a significant yet underaddressed concern in reconstructive surgery for oral cancer. While xenogeneic acellular dermal matrix (Xeno-ADM) is common in soft-tissue repair, its efficacy for fascia lata reconstruction at the ALT donor site remains insufficiently characterized. This study aimed to assess the efficacy of xeno-ADM in fascia lata repair, focusing on compartment pressure, inflammatory and muscle injury biomarkers, and functional recovery. METHODS: In this prospective, randomized, single-blind trial, 200 patients undergoing ALT flap reconstruction were allocated to Xeno-ADM repair (n = 100) or primary closure (n = 100). Primary endpoints included compartment pressure, inflammatory markers in drainage fluid, serum muscle injury biomarkers, and functional outcomes. RESULTS: The xeno-ADM group showed significantly lower compartment pressures throughout postoperative days (POD) 1-5. Inflammatory markers in drainage fluid (CRP on POD 3 and 5) and serum muscle injury biomarkers (creatine kinase on POD 1 and 5) were significantly lower in xeno-ADM group. Functional outcomes were superior in the Xeno-ADM group, with faster gait recovery, lower pain scores at POD 7, and better lower-limb function at the 1- and 6-month follow-ups. Drainage duration did not differ between groups. Stratified analyses revealed that the benefits of xeno-ADM were more pronounced in patients with defect width >3 cm or a body mass index ≥24 kg/m. CONCLUSION: Xeno-ADM provides a safe and effective approach for fascia lata repair, reducing biomechanical and inflammatory burdens while enhancing functional recovery. These findings support a transition from simple structural closure toward functional donor-site reconstruction.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.